摘要
目的:探讨抗心磷脂抗体与胎儿生长受限发生的关系,为胎儿生长受限的早期诊断和预防提供新的思路。方法:记录我院正常妊娠产妇及抗心磷脂抗体阳性产妇的妊娠结局、分娩方式、新生儿出生体重和Apgar′s评分,并进行回顾性分析。结果:胎儿生长受限组抗心磷脂抗体阳性者胎儿生长受限发生率为15.63%,对照组抗心磷脂抗体阴性者胎儿生长受限发生率为1.67%,两组比较,有显著性差异(P<0.05);胎儿生长受限组抗心磷脂抗体阳性比率为18.60%,对照组为3.36%,两组比较,有显著性差异(P<0.05)。结论:胎儿生长受限孕妇血清抗心磷脂抗体阳性在我院行产前检查的孕妇中明显升高,提示胎儿生长受限的发生与抗心磷脂抗体阳性有关。抗心磷脂抗体阳性是胎儿生长受限发生的病因之一。
Objective： To investigate the relationship of anticardiolipin antibody （ACA） and fetal growth restriction （FGR）, and to provide new methods for the early diagnosis and prevention of FGR. Methods： In our hospital, pregnancy outcome, pregnancy methods, birth weight and Apgar＇s score of normal pregnant women and pregnant women with ACA-positive were recorded, and retrospectively analyzed. Results： AcA-positive probability of occurrence of FGR in FGR group was 15.63%, compared with ACA-negative 1.67% of control group was significantly higher, there was a significant difference （P0.05）. FGR group of ACA-positive rate of 18.60% was significantly higher than 3.36% of the control group, there was a significant difference （P0.05）. Conclusion： FGR maternal serum ACA levels are significantly increased, indicating that there is a relationship of the occurrence of FGR and the ACA-positive. ACA-positive is one of the causes of FGR occurred.
出处
《中国医药导报》
CAS
2010年第29期36-37,共2页
China Medical Herald
关键词
胎儿生长受限
抗心磷脂抗体
产前检查
Fetal growth restriction
Anticardiolipin antibodiy
Pregnacy check-up
